In addition, it should be noted that ε2 carriers showed statistically lower levels of both total and pS9 GSK‐3β, (p = .009; p = .02) but their ratio (GSK‐3β activity, p = .99) remained unchanged compared with ε3 (Figure 1D, E), suggesting an overall reduction of GSK‐3β in ε2‐carried T2DM patients. Here, GSK3B is linked to type 2 diabetes mellitus.